Showing results (1-10 of 259) with videos related to
Sort By:
Pageof 26
Cancer Cell|February 13, 2024
Re-inventing a better wheel? Serplulimab for squamous cell lung cancerDerek De-Rui Huang, James Chih-Hsin YangJournal of the Formosan Medical Association = Taiwan Yi Zhi|January 29, 2025
Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumorsYen-Lin Huang, Chia-Chi Hsu, Derek De-Rui Huang, et al.Future Oncology (London, England)|February 16, 2023
Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summaryJames Chih-Hsin YangDrugs|December 24, 2010
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsChia-Chi Lin, James Chih-Hsin YangAnticancer Research|March 31, 2021
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung CancerSebastian Griesing, Bin-Chi Liao, James Chih-Hsin YangTherapeutic Advances in Medical Oncology|December 6, 2019
Second-line treatment of <i>EGFR</i> T790M-negative non-small cell lung cancer patientsBin-Chi Liao, Sebastian Griesing, James Chih-Hsin YangAnnual Review of Medicine|January 28, 2020
Precision Management of Advanced Non-Small Cell Lung CancerChing-Yao Yang, James Chih-Hsin Yang, Pan-Chyr YangClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2011
Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLCRené H Medema, Chia-Chi Lin, James Chih-Hsin YangCurrent Oncology Reports|February 1, 2017
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of AfatinibBin-Chi Liao, Chia-Chi Lin, James Chih-Hsin YangDrugs|March 13, 2013
First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developmentsBin-Chi Liao, Chia-Chi Lin, James Chih-Hsin YangPageof 26